サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1760465

動脈狭窄治療薬の世界市場レポート 2025年

Artery Stenosis Drug Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.09円
動脈狭窄治療薬の世界市場レポート 2025年
出版日: 2025年07月01日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

動脈狭窄治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は6.2％で、33億4,000万米ドルに成長します。予測期間に予測される成長は、肥満と糖尿病の有病率の上昇、低侵襲治療に対する需要の高まり、新興市場におけるヘルスケアアクセスの増加、ヘルスケア支出の増加、糖尿病と肥満率の継続的な上昇に起因しています。この期間の主な動向としては、個別化医療アプローチの採用、併用療法の拡大、診断技術の進歩、予防的心臓病学への注目の高まり、新規ドラッグデリバリーシステムの開発などが挙げられます。

糖尿病と肥満の有病率の上昇が、今後数年間の動脈狭窄治療薬市場の成長を牽引すると予想されます。糖尿病は、体内でインスリンの分泌が不足するか、インスリンを適切に使用できないために血糖値が上昇する慢性疾患であり、肥満は体脂肪過多を特徴とし、さまざまな健康問題のリスクを高めます。糖尿病と肥満の増加は、定期的な運動不足が主な原因であり、座りっぱなしの職場環境やスクリーンを使った余暇活動が、体重増加とインスリン抵抗性を助長しています。糖尿病も肥満も動脈へのプラーク蓄積を促進し、心臓発作や脳卒中のリスクを高めるため、動脈狭窄治療薬が不可欠となっています。例えば、2024年3月、世界保健機関（WHO）は、2022年には25億人の成人が太りすぎで、8億9,000万人が肥満と共存していると報告しました。その結果、糖尿病と肥満の有病率の増加が動脈狭窄治療薬市場の拡大に大きく寄与しています。

高コレステロール血症の治療における開発は、革新的な治療薬の開発を通じて動脈狭窄治療薬市場の成長を促進しています。同市場の主要企業は、高コレステロールの管理におけるアンメット・メディカル・ニーズに対応するため、ベンペド酸を含む治療薬に注力しています。ベンペド酸は、スタチン系薬剤に耐えられない患者や追加の脂質低下療法が必要な患者のLDLコレステロール値を低下させるために設計されたファースト・イン・クラスの薬剤です。例えば、2022年5月、インドの製薬会社ザイダス・ライフサイエンシズ社は、ベンペド酸を含有する高コレステロール血症の経口治療薬Bemdacを発売しました。この新しい治療選択肢は、肝臓でのコレステロール合成を標的とする新しいクラスの薬剤を提供するもので、スタチン系薬剤によく見られる筋肉関連の副作用を最小限に抑えながら、心血管系の転帰を改善することを目指しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場 - 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界動脈狭窄治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の動脈狭窄治療薬市場：成長率分析
  • 世界の動脈狭窄治療薬市場の実績：規模と成長、2019～2024年
  • 世界の動脈狭窄治療薬市場の予測：規模と成長、2024～2029年、2034年
  • 世界動脈狭窄治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の動脈狭窄治療薬市場：薬剤の種類別、実績と予測、2019～2024年、2024～2029年、2034年
  • 抗血小板薬
  • 抗凝固薬
  • スタチン
  • ベータ遮断薬
  • 世界の動脈狭窄治療薬市場：作用機序別、実績と予測、2019～2024年、2024～2029年、2034年
  • 血小板凝集阻害剤
  • トロンビン阻害剤
  • HMG-CoA還元酵素阻害剤
  • ベータアドレナリン拮抗薬
  • 世界の動脈狭窄治療薬市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
  • 経口
  • 注射
  • 経皮
  • 世界の動脈狭窄治療薬市場：患者タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 成人
  • 高齢者
  • 小児
  • 世界の動脈狭窄治療薬市場：抗血小板薬の種類別、実績と予測、2019～2024年、2024～2029年、2034年
  • アスピリン
  • クロピドグレル
  • チカグレロル
  • プラスグレル
  • ジピリダモール
  • 世界の動脈狭窄治療薬市場：抗凝固薬の種類別、実績と予測、2019～2024年、2024～2029年、2034年
  • ワルファリン
  • ヘパリン
  • 低分子量ヘパリン
  • 直接経口抗凝固薬（DOAC）
  • 世界の動脈狭窄治療薬市場：スタチンの種類別、実績と予測、2019～2024年、2024～2029年、2034年
  • アトルバスタチン
  • シンバスタチン
  • ロスバスタチン
  • プラバスタチン
  • ロバスタチン
  • 世界の動脈狭窄治療薬市場：ベータ遮断薬の種類別、実績と予測、2019～2024年、2024～2029年、2034年
  • メトプロロール
  • アテノロール
  • プロプラノロール
  • カルベジロール
  • ビソプロロール

第7章 地域別・国別分析

  • 世界の動脈狭窄治療薬市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
  • 世界の動脈狭窄治療薬市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 動脈狭窄治療薬市場：競合情勢
  • 動脈狭窄治療薬市場：企業プロファイル
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
    • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Bayer AG
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Abbott Laboratories
  • Novartis AG
  • Sanofi S.A.
  • GSK plc
  • Takeda Pharmaceutical Company Limited
  • Medtronic plc
  • Gilead Sciences Inc.
  • Amgen Inc.
  • Baxter International Inc.
  • Regeneron Pharmaceuticals Inc.
  • Lupin Limited
  • Alnylam Pharmaceuticals

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 動脈狭窄治療薬市場2029：新たな機会を提供する国
  • 動脈狭窄治療薬市場2029：新たな機会を提供するセグメント
  • 動脈狭窄治療薬市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r35342

Artery stenosis drugs are medications designed to manage and treat the narrowing of arteries, a condition known as stenosis, which can lead to reduced blood flow and various health complications. These medications aim to alleviate symptoms, prevent further progression, and reduce the risk of severe events such as heart attacks or strokes.

The primary types of artery stenosis drugs include antiplatelet agents, anticoagulants, statins, and beta-blockers. Antiplatelet agents work by preventing platelets from clumping together to form blood clots. This category includes platelet aggregation inhibitors, thrombin inhibitors, HMG-CoA reductase inhibitors, and beta-adrenergic antagonists. These drugs can be administered through various routes, including oral, injectable, and transdermal forms, and are prescribed to different patient groups, including adults, the elderly, and pediatric patients.

The artery stenosis drug market research report is one of a series of new reports from The Business Research Company that provides artery stenosis drug market statistics, including the artery stenosis drug industry's global market size, regional shares, competitors with an artery stenosis drug market share, detailed artery stenosis drug market segments, market trends and opportunities, and any further data you may need to thrive in the artery stenosis drug industry. This artery stenosis drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The artery stenosis drug market size has grown strongly in recent years. It will grow from $2.47 billion in 2024 to $2.63 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth observed in the historical period can be attributed to several factors, including the rising incidence of cardiovascular diseases, an expanding geriatric population, increased awareness about arterial health, a greater use of telemedicine for patient monitoring, and advancements in healthcare infrastructure.

The artery stenosis drug market size is expected to see strong growth in the next few years. It will grow to $3.34 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth projected for the forecast period can be attributed to the rising prevalence of obesity and diabetes, a growing demand for minimally invasive treatments, increased healthcare access in emerging markets, rising healthcare expenditures, and the continued rise in diabetes and obesity rates. Key trends during this period include the adoption of personalized medicine approaches, a greater use of combination therapies, advancements in diagnostic techniques, a heightened focus on preventative cardiology, and the development of novel drug delivery systems.

The rising prevalence of diabetes and obesity is expected to drive the growth of the artery stenosis drug market in the coming years. Diabetes is a chronic condition where the body either produces insufficient insulin or cannot use it properly, leading to elevated blood sugar levels, while obesity is characterized by excessive body fat, increasing the risk of various health problems. The increase in diabetes and obesity is largely attributed to the lack of regular physical activity, which is linked to sedentary work environments and screen-based leisure activities, contributing to weight gain and insulin resistance. Both diabetes and obesity promote plaque buildup in arteries, heightening the risk of heart attacks and strokes, making artery stenosis drugs essential. For example, in March 2024, the World Health Organization (WHO) reported that in 2022, 2.5 billion adults were overweight, with 890 million living with obesity. As a result, the growing prevalence of diabetes and obesity is significantly contributing to the expansion of the artery stenosis drug market.

Advancements in the treatment of hypercholesterolemia are driving growth in the artery stenosis drug market through the development of innovative therapeutics. Major companies in the market are focusing on therapies including bempedoic acid to address unmet medical needs in managing high cholesterol. Bempedoic acid is a first-in-class drug designed to lower LDL cholesterol levels in patients who cannot tolerate statins or need additional lipid-lowering therapy. For example, in May 2022, Zydus Lifesciences Ltd., an India-based pharmaceutical company, launched Bemdac, an oral therapy for hypercholesterolemia containing bempedoic acid. This novel treatment option offers a new class of drug that targets cholesterol synthesis in the liver, aiming to improve cardiovascular outcomes while minimizing muscle-related side effects commonly associated with statins.

In January 2023, AstraZeneca plc, a UK-based pharmaceutical company, acquired CinCor Pharma Inc. for $1.8 billion. This acquisition enhances AstraZeneca's position in the cardiorenal pipeline by adding CinCor's drug, baxdrostat, an aldosterone synthase inhibitor (ASI) designed to lower blood pressure in treatment-resistant hypertension. The acquisition supports AstraZeneca's commitment to delivering innovative therapies that address complex diseases and improve patient outcomes. CinCor Pharma Inc. is a US-based biopharmaceutical company, specializing in developing novel treatments for cardiorenal diseases.

Major players in the artery stenosis drug market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Novartis AG, Sanofi S.A., GSK plc, Takeda Pharmaceutical Company Limited, Medtronic plc, Gilead Sciences Inc., Amgen Inc., Baxter International Inc., Regeneron Pharmaceuticals Inc., Lupin Limited, and Alnylam Pharmaceuticals.

North America was the largest region in the artery stenosis drug market in 2024. The regions covered in artery stenosis drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the artery stenosis drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The artery stenosis drug market consists of sales of cholesterol-lowering drugs, calcium channel blockers, and hypertension medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Artery Stenosis Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on artery stenosis drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for artery stenosis drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The artery stenosis drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Drug Type: Antiplatelet Agents; Anticoagulants; Statins; Beta Blockers
  • 2) By Mechanism Of Action: Platelet Aggregation Inhibitors; Thrombin Inhibitors; HMG-CoA Reductase Inhibitors; Beta-Adrenergic Antagonists
  • 3) By Route Of Administration: Oral; Injectable; Transdermal
  • 4) By Patient Type: Adults; Geriatric; Pediatric
  • Subsegments:
  • 1) By Antiplatelet Agents: Aspirin; Clopidogrel; Ticagrelor; Prasugrel; Dipyridamole
  • 2) By Anticoagulants: Warfarin; Heparin; Low Molecular Weight Heparins; Direct Oral Anticoagulants (DOACs)
  • 3) By Statins: Atorvastatin; Simvastatin; Rosuvastatin; Pravastatin; Lovastatin
  • 4) By Beta Blockers: Metoprolol; Atenolol; Propranolol; Carvedilol; Bisoprolol
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; AbbVie Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Artery Stenosis Drug Market Characteristics

3. Artery Stenosis Drug Market Trends And Strategies

4. Artery Stenosis Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Artery Stenosis Drug Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Artery Stenosis Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Artery Stenosis Drug Market Growth Rate Analysis
  • 5.4. Global Artery Stenosis Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Artery Stenosis Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Artery Stenosis Drug Total Addressable Market (TAM)

6. Artery Stenosis Drug Market Segmentation

  • 6.1. Global Artery Stenosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Antiplatelet Agents
  • Anticoagulants
  • Statins
  • Beta Blockers
  • 6.2. Global Artery Stenosis Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Platelet Aggregation Inhibitors
  • Thrombin Inhibitors
  • HMG-CoA Reductase Inhibitors
  • Beta-Adrenergic Antagonists
  • 6.3. Global Artery Stenosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Injectable
  • Transdermal
  • 6.4. Global Artery Stenosis Drug Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Adults
  • Geriatric
  • Pediatric
  • 6.5. Global Artery Stenosis Drug Market, Sub-Segmentation Of Antiplatelet Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Aspirin
  • Clopidogrel
  • Ticagrelor
  • Prasugrel
  • Dipyridamole
  • 6.6. Global Artery Stenosis Drug Market, Sub-Segmentation Of Anticoagulants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Warfarin
  • Heparin
  • Low Molecular Weight Heparins
  • Direct Oral Anticoagulants (DOACs)
  • 6.7. Global Artery Stenosis Drug Market, Sub-Segmentation Of Statins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Atorvastatin
  • Simvastatin
  • Rosuvastatin
  • Pravastatin
  • Lovastatin
  • 6.8. Global Artery Stenosis Drug Market, Sub-Segmentation Of Beta Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Metoprolol
  • Atenolol
  • Propranolol
  • Carvedilol
  • Bisoprolol

7. Artery Stenosis Drug Market Regional And Country Analysis

  • 7.1. Global Artery Stenosis Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Artery Stenosis Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Artery Stenosis Drug Market

  • 8.1. Asia-Pacific Artery Stenosis Drug Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Artery Stenosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Artery Stenosis Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Artery Stenosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Artery Stenosis Drug Market

  • 9.1. China Artery Stenosis Drug Market Overview
  • 9.2. China Artery Stenosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Artery Stenosis Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Artery Stenosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Artery Stenosis Drug Market

  • 10.1. India Artery Stenosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Artery Stenosis Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Artery Stenosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Artery Stenosis Drug Market

  • 11.1. Japan Artery Stenosis Drug Market Overview
  • 11.2. Japan Artery Stenosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Artery Stenosis Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Artery Stenosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Artery Stenosis Drug Market

  • 12.1. Australia Artery Stenosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Artery Stenosis Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Artery Stenosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Artery Stenosis Drug Market

  • 13.1. Indonesia Artery Stenosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Artery Stenosis Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Artery Stenosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Artery Stenosis Drug Market

  • 14.1. South Korea Artery Stenosis Drug Market Overview
  • 14.2. South Korea Artery Stenosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Artery Stenosis Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Artery Stenosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Artery Stenosis Drug Market

  • 15.1. Western Europe Artery Stenosis Drug Market Overview
  • 15.2. Western Europe Artery Stenosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Artery Stenosis Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Artery Stenosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Artery Stenosis Drug Market

  • 16.1. UK Artery Stenosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Artery Stenosis Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Artery Stenosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Artery Stenosis Drug Market

  • 17.1. Germany Artery Stenosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Artery Stenosis Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Artery Stenosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Artery Stenosis Drug Market

  • 18.1. France Artery Stenosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Artery Stenosis Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Artery Stenosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Artery Stenosis Drug Market

  • 19.1. Italy Artery Stenosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Artery Stenosis Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Artery Stenosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Artery Stenosis Drug Market

  • 20.1. Spain Artery Stenosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Artery Stenosis Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Artery Stenosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Artery Stenosis Drug Market

  • 21.1. Eastern Europe Artery Stenosis Drug Market Overview
  • 21.2. Eastern Europe Artery Stenosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Artery Stenosis Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Artery Stenosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Artery Stenosis Drug Market

  • 22.1. Russia Artery Stenosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Artery Stenosis Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Artery Stenosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Artery Stenosis Drug Market

  • 23.1. North America Artery Stenosis Drug Market Overview
  • 23.2. North America Artery Stenosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Artery Stenosis Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Artery Stenosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Artery Stenosis Drug Market

  • 24.1. USA Artery Stenosis Drug Market Overview
  • 24.2. USA Artery Stenosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Artery Stenosis Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Artery Stenosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Artery Stenosis Drug Market

  • 25.1. Canada Artery Stenosis Drug Market Overview
  • 25.2. Canada Artery Stenosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Artery Stenosis Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Artery Stenosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Artery Stenosis Drug Market

  • 26.1. South America Artery Stenosis Drug Market Overview
  • 26.2. South America Artery Stenosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Artery Stenosis Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Artery Stenosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Artery Stenosis Drug Market

  • 27.1. Brazil Artery Stenosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Artery Stenosis Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Artery Stenosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Artery Stenosis Drug Market

  • 28.1. Middle East Artery Stenosis Drug Market Overview
  • 28.2. Middle East Artery Stenosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Artery Stenosis Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Artery Stenosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Artery Stenosis Drug Market

  • 29.1. Africa Artery Stenosis Drug Market Overview
  • 29.2. Africa Artery Stenosis Drug Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Artery Stenosis Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Artery Stenosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Artery Stenosis Drug Market Competitive Landscape And Company Profiles

  • 30.1. Artery Stenosis Drug Market Competitive Landscape
  • 30.2. Artery Stenosis Drug Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Artery Stenosis Drug Market Other Major And Innovative Companies

  • 31.1. Bayer AG
  • 31.2. Bristol-Myers Squibb Company
  • 31.3. AstraZeneca PLC
  • 31.4. Abbott Laboratories
  • 31.5. Novartis AG
  • 31.6. Sanofi S.A.
  • 31.7. GSK plc
  • 31.8. Takeda Pharmaceutical Company Limited
  • 31.9. Medtronic plc
  • 31.10. Gilead Sciences Inc.
  • 31.11. Amgen Inc.
  • 31.12. Baxter International Inc.
  • 31.13. Regeneron Pharmaceuticals Inc.
  • 31.14. Lupin Limited
  • 31.15. Alnylam Pharmaceuticals

32. Global Artery Stenosis Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Artery Stenosis Drug Market

34. Recent Developments In The Artery Stenosis Drug Market

35. Artery Stenosis Drug Market High Potential Countries, Segments and Strategies

  • 35.1 Artery Stenosis Drug Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Artery Stenosis Drug Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Artery Stenosis Drug Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer